<DOC>
	<DOCNO>NCT02485106</DOCNO>
	<brief_summary>This study aim investigate effect decontamination rifaximin severe alcoholic hepatitis patient . Patients take corticosteroid pentoxifylline randomly allocate rifaximin group control group .</brief_summary>
	<brief_title>Rifaximin Use Severe Alcoholic Hepatitis</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Alcoholic</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<criteria>Heavy alcohol drinking within 3 month ( Over 40 g/day ) Maddrey 's discriminant function ≥ 32 AST/ALT ration ≥ 2 Bilirubin level ≥ 5mg/dL Any one follow additional criterion : hepatic encephalopathy , enlarge , tender liver , peripheral leucocytosis Age : 1975 Jaundice within 3 month Other cause chronic liver disease ( HBV , HCV , autoimmune hepatitis ) Antibiotics probiotic use within 8 week Drug induce hepatotoxicity Acute viral hepatitis ( HAV HEV ) Hepatic abscess cholagitis Hepatocellular carcinoma modify UICC stage II , III IV Malignant tumor HCC Pregnancy Severe chronic extrahepatic disease Type I hepatorenal syndrome Hepatic encephalopathy grade II IV Severe infection</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>